Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Patients With Obese and HFpEF: A Randomized Controlled Trial

NCT07630454 is registered in ClinicalTrials.gov with Yunlong Wang as lead sponsor.

NCT NCT07630454
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07630454 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Patients With Obese and HFpEF: A Randomized Controlled Trial
Lead sponsor
Yunlong Wang
Phase
Phase 4
Overall status
Not yet recruiting
Start date
August 1, 2026
Completion date
December 1, 2029
Enrollment
602 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation, heart failure with preserved ejection fraction (hfpef), tirzepatide